Abstract
Mast cell-derived prostaglandin D2 (PGD2) is one of the essential modulators of eosinophilic airway inflammation in asthma and allergic rhinitis. Two G protein-coupled receptors for PGD2, prostaglandin D2 receptor (DP) and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2), are both expressed on the surface of eosinophils, and CRTH2 has been demonstrated to mediate PGD2-induced eosinophil mobilization in vitro. However, it has not yet been determined whether PGD2 and its receptors mediate in vivo eosinophil trafficking into the airways or other organs. We demonstrated that intratracheal administration of PGD2 in rats pretreated with systemic interleukin-5 (IL-5) injection induced marked airway eosinophilia, determined by the differential counts of cells in bronchoalveolar lavage (BAL) fluid and lung histology, within 2 h. Systemic IL-5 alone significantly increased the number of eosinophils in the peripheral blood but showed no effect on airway eosinophilia. Three CRTH2-specific agonists (13,14-dihydro-15-keto-PGD2, 11-deoxy-11-methylene-15-keto-PGD2, and indomethacin) demonstrated equivalent induction of BAL eosinophilia to that of PGD2, but a DP agonist (BW 245C [5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)-hydantoin]) or a thromboxane A2 receptor (TP) agonist ([1S-1α,2β(5Z), 3α(1E,3R*),4α)]-7-[3-(3-hydroxy-4-(4′-iodophenoxy)-1-butenyl)-7-oxabicyclo-[2.2.1]heptan-2-yl]-5-heptenoic acid) showed no effect. PGD2 or CRTH2 agonist-induced BAL eosinophilia was almost completely inhibited by pretreatment with a CRTH2/TP antagonist, ramatroban [BAY-u3405; (+)-(3R)-3-(4-fluorobenzenesulfonamido)-1,2,3,4-tetra-hydrocarbazole-9-propionic acid], whereas a TP-specific antagonist, SQ29,548 (5-heptenoic, 7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]-hept-2-yl]-[1S-[1α,2α(Z),3α,4α]]), or a DP-specific antagonist, BW A868C [3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexy-2-hydroxyethylamino)-hydantoin], did not inhibit the effects of PGD2. These results suggest that CRTH2 plays a significant role in the eosinophil trafficking from the bloodstream into the airways in PGD2-related airway inflammation.
Footnotes
-
Y.S. received a fellowship from the Foundation of the Association for Preventive Medicine of Japan. This work was partially supported by a grant-in-aid from the Japanese Ministry of Health, Labor and Welfare.
-
doi:10.1124/jpet.104.078212.
-
ABBREVIATIONS: PGD2, prostaglandin D2; BW 245C, 5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)-hydantoin; DK-PGD2, 13,14-dihydro-15-keto PGD2; IL-5, interleukin-5; PBS, phosphate-buffered saline; MK-PGD2, 11-deoxy-11-methylene-15-keto PGD2; TP, thromboxane A2 receptor; I-BOP, [1S-1α,2β(5Z),3α(1E,3R*),4α)]-7-[3-(3-hydroxy-4-(4′-iodophenoxy)-1-butenyl)-7-oxabicyclo-[2.2.1]heptan-2-yl]-5-heptenoic acid; BAY-u3405, (+)-(3R)-3-(4-fluorobenzenesulfonamido)-1,2,3,4-tetra-hydrocarbazole-9-propionic acid; BW A868C, 3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexy-2-hydro-xyethylamino)-hydantoin; SQ29,548, 5-heptenoic, 7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-[1S-[1α,2α(Z),3α,4α]]; BAL, bronchoalveolar lavage; DP, prostaglandin D2 receptor; CRTH2, chemoattractant receptor-homologous molecule expressed on Th2 cells; S-5751, (Z)-7-[(1R,2R,3S,5S)-2-(5-hydroxybenzo[b]thiophen-3-ylcarbonylamino)-10-norpinan-3-yl]hept-5-enoic acid.
- Received September 21, 2004.
- Accepted November 2, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|